Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events compared with low molecular weight heparins (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors may leads to lower ALT >3 times the upper normal limit compared with low molecular weight heparins (low certainty).
1 finding from 1 review
Death from all causes (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Recurrence of pulmonary emboli · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower recurrence of pulmonary emboli (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Major bleeding · patients with acute pulmonary embolism
Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).
1 finding from 1 review
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES may leads to higher total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in asymptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in symptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
PE · participants at risk of venous thromboembolism
1 finding from 1 review
Total VTE · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Bleeding ‐ clinically indicated non‐major Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review